A stable, non-peptide inhibitor of the protease from type 1 human immunodeficiency virus has been developed, and the stereochemistry of binding defined through crystallographic three-dimensional structure determination. The initial compound, haloperidol, was discovered through computational screening of the Cambridge Structural Database using a shape complementarity algorithm. The subsequent modification is a non-peptidic lateral lead, which belongs to a family of compounds with well characterized pharmacological properties. This thioketal derivative of haloperidol and a halide counterion are bound within the enzyme active site in a mode distinct from that observed for peptidebased inhibitors. A variant of the protease cocrystallized with this inhibitor shows binding in the manner predicted during the initial computer-based search. The structures provide the context for subsequent synthetic modifications of the inhibitor.
place a high premium on development of organic compounds as leads that avoid these problems. Over 10 million chemical compounds have been characterized (13) , and the crystallographically determined threedimensional structures of a subset are available in the Cambridge Structural Database (CSD) (14, 15) . Other structures can be predicted using software such as CONCORD (16) . Effective computational screening of these structures would greatly assist in drug discovery.
A computational search of the CSD was based on shape and to some extent on possible chemical complementarity with the active site of HIV-1 protease (17) (18) (19) . Approximately 50 of the top scoring 200 compounds were commercially available, and 15 were assayed for inhibition. Of these, five were inhibitory in the range of 10 PM to 1 m M and one, haloperidol (UCSF1) (Fig.  lA) , was selected for subsequent improvement. UCSFl is inhibitory with an apparent Ki (inhibition constant) = 100 VM for HIV-1 protease. Replacement of the ketone functional center with a thioketal ring (1,3-dithiolane) resulted in UCSF8 (Fig.   1B ). UCSF8 is a competitive inhibitor with an apparent Ki of 15 2 2 VM (Fig. 1C) for HIV-1 protease, and the inhibition constant is highly dependent upon the concentration of NaC1, NaBr, NaI, and NaF. The Ki of UCSF8 for HIV-2 protease is 100 VM. Selectivity of UCSF8 for HIV-1 protease over pepsin is over 40-fold, whereas it is approximately 100-fold or greater for renin and cathepsin D based on the ratios of ICBo values. The complex of this improved inhibitor with HIV-1 protease was crystallized and the structure solved t o 2.2-A resolution (Table I ). The same inhibitor was also cocrystallized with a variant HIV-1 protease designed to beo more proteolytically stable and the structure solved to 1.9-A resolution. Cocrystallization of UCSF8 and HIV-1 protease gave tetragonal bipyramidal crystals in space group P41, whereas cocrystallization of UCSF8 and HIV-1 protease Q7K gave orthorhombic plates in space group P212121.
Both structures were solved by isomorphous molecular replacement using a partial model of the dimer generated from the chemically synthesized unliganded enzyme structure, 3HVP (6) . Together, these structures reveal distinct binding modes of this inhibitor within the active site cavity and define specific strategies for future inhibitor design.
The largest difference between the UCSF8-HIV-1 protease structure and previously reported structures of HIV-1 protease is the unique conformation of the active site flaps (Fig. 2C 1. The conformation of the flaps is intermediate between that in the unliganded enzyme and that of the peptide analog-bound structures, as demonstrated by principal axes analysis (20) .
A chloride anion is coordinated between the bound inhibitor and the almost symmetric amide nitrogens of Ile-50 and Ile-150 in the flaps that surround the active site (Fig. 2C) . The distances between the chloride position and the coordinatiag heavy atoms are similar to the interatomic distance (-3.2 A) observed between a chloride and a charged or uncharged nitrogen involved in an electrostatic interaction in crystallographically determined small molecule structures (21, 22) .
UCSF8 is clearly defined in continuous density in a complexminus-protein difference map and lies in relatively extended conformation. The two 2-fold related and partially overlapping binding modes for the inhibitor are each about 50% occupied (Fig. 2 A ) . Thus, the inhibitor density was interpreted and refined as two overlapping structures constrained by a non-crystallographic 2-fold axis. by UCSF8. A plot (inset) of the slopes from the Dixon plot uersus the reciprocal of substrate concentration indicates that UCSFS acts as a competitive inhibitor. UCSF8 was obtained by reaction of haloperidol with 1,2-ethanedithiol with a 99% yield. Purification was accomplished by filtration through a silica gel column. The resulting crystalline product had a melting point of 101.0-102.5 "C. Elemental analysis and 'H NMR, infrared, and mass spectra are consistent with the assigned structure. Purified HIV-1 protease (1.93 x mg/ml) was incubated with UCSF8 in 50 mM sodium acetate buffer, pH 5.5, containing 1 mM dithiothreitol, 1 mM EDTA, 1 M NaC1, and 5% Me2S0. After 1 min, the substrate (Peptide I) was added to give the final substrate concentrations shown (abscissa). The assay solutions were incubated for 5 min at 37 "C, and enzyme activity was determined by quantifying the hydrolysis products on high performance liquid chromatography.
ual difference density at the inhibitor sites, indicating that the single binding mode, averaged by statistical occupation, accounts for all the density in the map. oThe higher thermal , B factors for atoms of UCSF8 ((B) = 68.6 A') versus ( B ) = 30.3 A' for all atoms in the protein, indicate that the inhibitor lies in a shallow energy mjnimum with root mean square amplitude of vibration, u = 0.9A, but it is not bound in other modes. In sum, the amino acid residues around the inhibitor binding site lie in well ordered density; the inhibitor lies in clear but less resolved density.
The UCSF8 binding site is on the opposite surface of the active site relative to the peptidomimetic inhibitor (JG365) (8) (Fig. 2 A ) . The five-membered, two-sulfur-containing thioketal ring extends into the P2 substrate binding pocket of the enzyme (23) and represents the only overlap with the volume of the active site occupied by peptidomimetic inhibitors (Fig. 2.4 1. tration of UCSF8 (-400 mM) with 3 pl of buffer A (1.0 M NaCl, 20.0 mM sodium acetate, pH 5.4). The drops were equilibrated against bufferAat 23 "C. Crystals up to 40 pm x 200 pm in dimension generally grew in 3-5 days. Diffraction intensities were recorded on a multiwire detector (Siemens X-100) using Cu K a x-rays from a rotating anode generator (Rigaku Ru300) with a graphite monochromator. Intensities were integrated using BUDDHA (281, and frame to frame scaling was carried out using XENGEN (29) . The structures were solved by isomorphous molecular replacement using a partial model of the dimer generated from the chemically synthesized unliganded enzyme structure, 3HVP (6). Coordinates will be deDosited in the Brookhaven Protein Data Bank.
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Crystallographic data The mutant protein, HIV-1 protease Q7K, has a similar inhibition profile, similar kinetic parameters, and a more than 100-fold greater stability toward proteolytic degradation than the wild-type enzyme (24) . The structure of UCSF8 in complex with HN-1 protease Q7K reveals two molecules of UCSF8 bound in the active site of the enzyme (Fig. 2B) , each with a chloride ion ligated by the piperidine nitrogen. The orientation of UCSF8 in the primary site is similar to that identified by the DOCK algorithm (Fig. 3) . The active site flaps are closed as in peptide-based inhibitor complexes of HIV-1 protease. The crystallographic observation of these various binding modes suggests that they are all of similar energy. These independent sites will be exploited by iterative structure-based drug development.
UCSF8 binds to HIV-1 protease 4.8 a away and rotated by 79" from the orientation predicted in the computational search. Furthermore, the bound conformation differs from the CSD structure used to make the prediction (17) (Fig. 2 A ) . This result can be accounted for in part by the simplifying assumptions used in the original shape complementarity algorithm. 1) Molecular water and counterions were not considered; 2) only steric interactions were considered; 3) a fixed crystallographically determined conformation of a chemically different compound was used; 4) a fixed conformation of the protein, that of the unliganded protease, was assumed. 
